Treatment of gout

Abstract

Sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio) acetate is described. In addition, pharmaceutical compositions and uses such compositions for the treatment of a variety of diseases and conditions.

1 . A method of treating gout comprising co-administration of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate, or a pharmaceutically acceptable salt thereof, and colchicine to a subject. 
     
     
         2 . The method of  claim 1 , wherein said method provides greater mean gout flare reduction than co-administration of colchicine and a therapeutic agent that is not a dual inhibitor of URAT1 and an inflammasome. 
     
     
         3 . The method of  claim 1 , wherein the total dosage of colchicine administered during co-administration with 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate, or a pharmaceutically acceptable salt thereof, is at least 50% less than the total dosage of colchicine that would be required for a similar effect when co-administered with a therapeutic agent that is not a dual inhibitor of URAT1 and an inflammasome. 
     
     
         4 . The method of  claim 1 , wherein the amount of time that colchicine is co-administered with 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate, or a pharmaceutically acceptable salt thereof, is at least one week less than would be required for a similar effect when colchicine is co-administered with a therapeutic agent that is not a dual inhibitor of URAT1 and an inflammasome. 
     
     
         5 . A method of reducing monosodium urate induced inflammation in a subject in need thereof, the method comprising administering a pharmaceutical composition comprising a pharmaceutical agent having both uricosuric and anti-inflammatory activity. 
     
     
         6 . The method of  claim 5  wherein the pharmaceutical agent is a URAT1 inhibitor with anti-inflammatory activity. 
     
     
         7 . The method of  claim 5  wherein the pharmaceutical agent is 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate, or a pharmaceutically acceptable salt thereof. 
     
     
         8 . The method of  claim 1  wherein the daily dose of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate, or a pharmaceutically acceptable salt thereof, is about 750 mg. 
     
     
         9 . The method of  claim 1  wherein the daily dose of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate, or a pharmaceutically acceptable salt thereof, is about 600 mg. 
     
     
         10 . The method of  claim 1  wherein the daily dose of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate, or a pharmaceutically acceptable salt thereof, is about 500 mg. 
     
     
         11 . The method of  claim 1  wherein the daily dose of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate, or a pharmaceutically acceptable salt thereof, is about 400 mg. 
     
     
         12 . The method of any of  claim 1  wherein the daily dose of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate, or a pharmaceutically acceptable salt thereof, is about 200 mg. 
     
     
         13 . The method of  claim 12  wherein the daily dose is administered orally. 
     
     
         14 . The method of  claim 12  wherein the daily dose is administered in the morning. 
     
     
         15 . The method of  claim 12  wherein the daily dose is administered with food. 
     
     
         16 . The method of  claim 12  further comprising administration of a second serum uric acid lowering agent. 
     
     
         17 . The method of  claim 16  wherein the second serum uric acid lowering agent is a xanthine oxidase inhibitor. 
     
     
         18 . The method of  claim 16  wherein the xanthine oxidase inhibitor is febuxostat or allopurinol.